FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BEAVER CAROLYN
2. Issuer Name and Ticker or Trading Symbol

ORGANOVO HOLDINGS, INC. [ ONVO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

6275 NANCY RIDGE DRIVE, SUITE 110
3. Date of Earliest Transaction (MM/DD/YYYY)

9/5/2019
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $0.266  9/5/2019    A     52000       (1) 9/5/2029  Common Stock  52000  $0.00  52000  D   

Explanation of Responses:
(1)  The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BEAVER CAROLYN
6275 NANCY RIDGE DRIVE, SUITE 110
SAN DIEGO, CA 92121
X



Signatures
/s/ Jennifer Bush, as attorney-in-fact 9/9/2019
**Signature of Reporting Person Date


Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Organovo Charts.
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Organovo Charts.

Organovo Holdings, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Friday 26 July 2024 (1 week ago) • Edgar (US Regulatory)
Form 8-K - Current report
Wednesday 24 July 2024 (1 week ago) • Edgar (US Regulatory)
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Tuesday 16 July 2024 (3 weeks ago) • GlobeNewswire Inc.
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 31 May 2024 (2 months ago) • Edgar (US Regulatory)
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Tuesday 21 May 2024 (2 months ago) • GlobeNewswire Inc.
Form 424B4 - Prospectus [Rule 424(b)(4)]
Tuesday 14 May 2024 (3 months ago) • Edgar (US Regulatory)
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Tuesday 14 May 2024 (3 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Monday 13 May 2024 (3 months ago) • Edgar (US Regulatory)
Form 424B4 - Prospectus [Rule 424(b)(4)]
Friday 10 May 2024 (3 months ago) • Edgar (US Regulatory)
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Wednesday 8 May 2024 (3 months ago) • GlobeNewswire Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Monday 15 April 2024 (4 months ago) • GlobeNewswire Inc.
Form EFFECT - Notice of Effectiveness
Thursday 8 February 2024 (6 months ago) • Edgar (US Regulatory)